Display options
Cite
Glick M, Baxter C, Lopez D, et al. Releasing the brakes: a case report of pulmonary arterial hypertension induced by immune checkpoint inhibitor therapy. Pulm Circ. 2020;10(4):2045894020960967doi: 10.1177/2045894020960967.
Glick, M., Baxter, C., Lopez, D., Mufti, K., Sawada, S., & Lahm, T. (2020). Releasing the brakes: a case report of pulmonary arterial hypertension induced by immune checkpoint inhibitor therapy. Pulmonary circulation, 10(4), 2045894020960967. https://doi.org/10.1177/2045894020960967
Glick, Matthew, et al. "Releasing the brakes: a case report of pulmonary arterial hypertension induced by immune checkpoint inhibitor therapy." Pulmonary circulation vol. 10,4 (2020): 2045894020960967. doi: https://doi.org/10.1177/2045894020960967
Glick M, Baxter C, Lopez D, Mufti K, Sawada S, Lahm T. Releasing the brakes: a case report of pulmonary arterial hypertension induced by immune checkpoint inhibitor therapy. Pulm Circ. 2020 Nov 11;10(4):2045894020960967. doi: 10.1177/2045894020960967. eCollection 2020. PMID: 33240485; PMCID: PMC7675877.
Copy Download .nbib Format: NLM
Share it on

Pulm Circ. 2020 Nov 11;10(4):2045894020960967. doi: 10.1177/2045894020960967. eCollection 2020.

Releasing the brakes: a case report of pulmonary arterial hypertension induced by immune checkpoint inhibitor therapy.

Pulmonary circulation

Matthew Glick, Chase Baxter, David Lopez, Kashif Mufti, Stephen Sawada, Tim Lahm

Affiliations

  1. Internal Medicine Residency Program, Department of Medicine, Indiana University School of Medicine, Indianapolis, USA.
  2. Department of Medicine, Division of Rheumatology, Indiana University School of Medicine, Indianapolis, USA.
  3. Department of Medicine, Krannert Institute of Cardiology, Indiana University School of Medicine, Indianapolis, USA.
  4. Department of Medicine, Division of Pulmonary, Critical Care, Sleep and Occupational Medicine, Indiana University School of Medicine, Indianapolis, USA.
  5. Richard L. Roudebush VA Medical Center, Indianapolis, USA.

PMID: 33240485 PMCID: PMC7675877 DOI: 10.1177/2045894020960967

Abstract

Immune checkpoint inhibitors successfully treat various malignancies by inducing an immune response to tumor cells. However, their use has been associated with a variety of autoimmune disorders, such as diabetes, hepatitis, and pneumonitis. Pulmonary arterial hypertension due to checkpoint inhibitor use has not yet been described. We present a novel case of pulmonary arterial hypertension associated with systemic lupus erythematosus and Sjogren's syndrome overlap that was induced by therapy with the checkpoint inhibitor durvalumab.

© The Author(s) 2020.

Keywords: autoimmune disease; durvalumab; immunotherapy; programmed death-ligand 1 inhibitor; right heart failure

Conflict of interest statement

Conflict of interest: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: TL has received consultancy fee

References

  1. Eur Respir J. 2019 Jan 24;53(1): - PubMed
  2. Am J Respir Crit Care Med. 2007 Jun 15;175(12):1280-9 - PubMed
  3. Thorax. 2015 Apr;70(4):382-7 - PubMed
  4. Circ Res. 2018 Jun 8;122(12):1689-1702 - PubMed
  5. Front Pharmacol. 2017 Feb 08;8:49 - PubMed
  6. RMD Open. 2016 Sep 28;2(2):e000321 - PubMed
  7. Immunol Rev. 2010 Jul;236:219-42 - PubMed
  8. Eur Heart J Cardiovasc Imaging. 2019 Feb 1;20(2):243 - PubMed
  9. Oncol Lett. 2017 Nov;14(5):5671-5680 - PubMed
  10. Autoimmun Rev. 2018 Jun;17(6):610-616 - PubMed

Publication Types